Literature DB >> 25133896

Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.

C S Chim1, K Y Wong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25133896     DOI： 10.1038/bmt.2014.192

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

2.  Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Authors:  Heinz Ludwig; Hedwig Kasparu; Clemens Leitgeb; Elisabeth Rauch; Werner Linkesch; Niklas Zojer; Richard Greil; Adelheid Seebacher; Ludek Pour; Adalbert Weißmann; Zdenek Adam
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

3.  Targeting the BRAF V600E mutation in multiple myeloma.

Authors:  Mindaugas Andrulis; Nicola Lehners; David Capper; Roland Penzel; Christoph Heining; Jennifer Huellein; Thorsten Zenz; Andreas von Deimling; Peter Schirmacher; Anthony D Ho; Hartmut Goldschmidt; Kai Neben; Marc S Raab
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

4.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

5.  Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.

Authors:  Mohamad A Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M Rifkin; Ralph Ellison
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

6.  A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

Authors:  James R Berenson; Jeffrey Matous; Regina A Swift; Russell Mapes; Blake Morrison; Howard S Yeh
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

7.  Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript.

Authors:  Margaret H L Ng; K M Lau; W S Wong; K W To; S H Cheng; K S Tsang; Natalie P H Chan; Bonnie C S Kho; K W Lo; Joanna H M Tong; C W Lam; Joyce C W Chan
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

8.  Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.

Authors:  Chor Sang Chim; Yu Yan Hwang; Clara Pang; Tony W Shek
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

9.  Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.

Authors:  Chor Sang Chim; Albert Kwok Wai Lie; Eric Yuk Tat Chan; Herman Sung Yu Liu; Ching Wa Lau; Sze Fai Yip; Joycelyn Sim; Thomas Shek-Kong Wan; Edmond Shiu-Kwan Ma; Raymond Liang; Eric Tse; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2012-06-08       Impact factor: 17.388

10.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962
View more
  1 in total

1.  Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma.

Authors:  Kwan Yeung Wong; Qiumei Yao; Ling-Qing Yuan; Zhenhai Li; Edmond Shiu Kwan Ma; Chor Sang Chim
Journal:  Sci Rep       Date:  2018-09-10       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.